Want to see PCVX full AI Analyst Report?
PCVX Stock Chart & Stats
$54.66
-$0.98(-1.76%)
At close: 4:00 PM EDT
$54.66
-$0.98(-1.76%)
Day’s Range― - ―
52-Week Range$29.08 - $65.00
Previous CloseN/A
Volume1.12M
Average Volume (3M)1.56M
Market Cap
$7.81B
Enterprise Value$6.49K
Total Cash (Recent Filing)$1.74B
Total Debt (Recent Filing)$116.30M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 12, 2026EPS Estimate
-2.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.89
Shares Outstanding144,397,670
10 Day Avg. Volume927,745
30 Day Avg. Volume1,559,662
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-9.38
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$110.60Price Target Upside102.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-8.38
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable Equity BaseA strong balance sheet with low debt and multi-billion dollars of equity provides durable financial flexibility to fund clinical programs, negotiate partnerships, and withstand development setbacks without immediate insolvency risk. It lengthens runway for strategic options such as collaborations or staged investment.
Proprietary CSP Platform And Pneumococcal FocusA differentiated carrier-sparing polysaccharide platform aimed at broader pneumococcal serotype coverage is a durable competitive asset in vaccines. If clinical success occurs, the platform can create product differentiation, sustain IP barriers, and attract long-term licensing or co-development partners in a structurally attractive vaccine market.
Board Strengthening And Governance ContinuityAddition of seasoned industry leadership and shareholder re-elections signal stronger strategic oversight and continuity. Durable governance and specialized board expertise (supply/manufacturing strategy) improve likelihood of operational execution, scale-up planning, and credibility with partners and regulators over the coming years.
Bears Say
No Commercial RevenueAbsent product revenue, the company must rely on financings or partnerships to fund R&D and operations. This structural lack of commercial cash inflows increases execution risk, compresses strategic optionality, and delays any pathway to self-sustaining operations until regulatory approvals and product launches occur.
High And Rising Cash BurnEscalating operating cash outflows and deeply negative free cash flow materially increase financing needs and potential dilution. Over months-to-years this pressures strategic choices: accelerate partner deals, cut programs, or raise capital—each impacting long-term value creation and execution certainty.
Persistent Negative Returns On EquitySustained negative ROE indicates that invested capital is not producing shareholder returns and signals capital consumption without commercial payoff. Without successful product approval and commercialization, reversing negative ROE requires material shifts in revenue generation or profitable partnerships, a multi-quarter to multi-year challenge.
Vaxcyte News
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $29.08 and its highest was $65.00 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Vaxcyte, Inc.’s market cap is $7.81B.
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 9 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on May 06, 2026. The company reported -$2.3 earnings per share for the quarter, missing the consensus estimate of -$1.778 by -$0.522.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -2.06.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 144,397,670 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$2.3 in its last earnings report, missing expectations of -$1.778. Following the earnings report the stock price went down -9.842%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Currently, no hedge funds are holding shares in PCVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vaxcyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$110.60 (102.34% Upside)
$110.60 (102.34% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.88%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
PCVX Stock 12 Month Forecast
Average Price Target
$110.60
▲(102.34% Upside)
Technical Analysis
Ownership Overview
0.76% Insiders
39.37% Mutual Funds
0.27% Other Institutional Investors
41.79% Public Companies and
Individual Investors